• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Brainstorm Cell Therapeutics Inc. (Amendment)

    2/12/24 10:06:24 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCLI alert in real time by email
    SC 13G/A 1 tm245889d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

    Brainstorm Cell Therapeutics Inc.

    (Name of Issuer)

     

    Common Stock, $0.00005 par value

    (Title of Class of Securities)

     

    10501E 201

    (CUSIP Number)

     

    Febuary 14, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨   Rule 13d-1(b)
    x   Rule 13d-1(c)
    ¨   Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 10501E 201

     

    1.  

    Names of Reporting Persons

    Kevin D. Ness 

     

    2.   Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)   ¨
        (b)  

    ¨

     

    3.  

    SEC Use Only

     

    4.   Citizenship or Place of Organization
    Canada 

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0

     

    6.

    Shared Voting Power

    3,060,000 (1)

     

    7.

    Sole Dispositive Power

    0

     

    8.

    Shared Dispositive Power

    3,060,000 (1)

     

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,060,000 (1) 

     

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    6.25% (2)

     

    12.  

    Type of Reporting Person (See Instructions)

    IN

     

    (1)Consists of (i) 2,600,000 shares of common stock held directly by the Reporting Person and the Reporting Person’s spouse, (ii) 160,000 shares of common stock held by the Ness Family Foundation, over which the Reporting Person and his spouse share voting and dispositive power, and (iii) 300,000 shares of common stock held by 1489 and 100 Vail Road Mortgage, an entity over which the Reporting Person and his spouse share voting and dispositive power.

     

    (2)

    Percentage of class is calculated based on 48,981,588 shares of common stock outstanding as of November 13, 2023, as reported by Brainstorm in their 10-Q filing to the SEC .

     

    1

     

    CUSIP No. 10501E 201

     

    Item 1.    
      (a) Name of Issuer
       

    Brainstorm Cell Therapeutics Inc.

     

      (b) Address of Issuer's Principal Executive Offices
        1325 Avenue of Americas, 28th Floor, New York, NY 10019
         
    Item 2.    
      (a) Name of Persons Filing
        Kevin D. Ness (the “Reporting Person”)
         
      (b) Address of Principal Business Office or, if none, Residence
       

    The principal business address for the Reporting Person is:

    2121 N. California Blvd., Suite 610

    Walnut Creek, CA 94596

     

      (c) Citizenship
       

    The Reporting Person is a citizen of Canada.

     

      (d) Title of Class of Securities
       

    Common Stock, $0.00005 par value

     

      (e) CUSIP No.
       

    10501E 201

     

    Item 3.   If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
        Not Applicable

     

    Item 4.

     

    Ownership

       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in
    Item 1.

     

      (a)

    Amount beneficially owned:

    3,060,000 shares of Common Stock

     

      (b) Percent of class: 6.25%

     

      (c) Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    0 shares of Common Stock

     

      (ii)

    Shared power to vote or to direct the vote:

    3,060,000 shares

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    0 shares of Common Stock

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    3,060,000 shares

     

    2

     

    CUSIP No. 10501E 201

     

    The securities reported above consist of (i) 2,600,000 shares of common stock held directly by the Reporting Person and the Reporting Person’s spouse, (ii) 160,000 shares of common stock held by the Ness Family Foundation, over which the Reporting Person and his spouse share voting and dispositive power, and (iii) 300,000 shares of common stock held by 1489 and 100 Vail Road Mortgage, an entity over which the Reporting Person and his spouse share voting and dispositive power. The reported beneficial ownership percentage is calculated based on 48,981,588 shares of common stock outstanding as of November 13, 2023, as reported by Brainstorm in their 10-Q filing to the SEC .

     

    Item 5. Ownership of Five Percent or Less of a Class
      Not Applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group
      Not Applicable.
       
    Item 10. Certification
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Sec. 240.14a-11.

     

    3

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: Febuary 8, 2024

     

      Kevin D. Ness
           
      By:    /s/ Kevin D. Ness
          Name: Kevin D. Ness

     

    4

     

    Get the next $BCLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Lebovits Chaim bought $11,308 worth of shares (23,836 units at $0.47), decreasing direct ownership by 93% to 80,960 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      10/2/24 8:00:14 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: President & CEO Lebovits Chaim bought $7,774 worth of shares (15,000 units at $0.52), increasing direct ownership by 1% to 1,164,865 units (SEC Form 4)

      4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      7/31/24 4:09:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: President & CEO Lebovits Chaim bought $30,475 worth of shares (50,000 units at $0.61), increasing direct ownership by 5% to 1,149,865 units (SEC Form 4)

      4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      7/31/24 4:08:32 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

      NEW YORK, May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey. This partnership supports

      5/27/25 7:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

      Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).  The trial design was previously agreed upon with the FDA under a Special Protocol Assessment (SPA), confirming the study's endpoints and statistical methodology are appropriate to support a future Biologics License Application (BLA) submissio

      5/19/25 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "BrainStorm continues to make meaningful progress in advancing our NurOwn® development program. Our priority continues to be initiation of a Phase 3b trial, designed to confirm the product's efficacy in early stage ALS patients and support a new BLA," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We h

      5/15/25 4:05:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Dagher Ibrahim B. was granted 50,000 shares, increasing direct ownership by 297% to 66,849 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/7/25 4:11:08 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: New insider Dagher Ibrahim B. claimed ownership of 505,742 shares (SEC Form 3)

      3/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/7/25 4:10:10 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President & CEO Lebovits Chaim was granted 120,000 shares, increasing direct ownership by 148% to 200,960 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/3/25 5:36:42 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    SEC Filings

    See more
    • Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      5/19/25 4:10:20 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Brainstorm Cell Therapeutics Inc.

      DEFA14A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      5/16/25 7:05:15 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Brainstorm Cell Therapeutics Inc.

      DEF 14A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      5/16/25 7:00:31 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Financials

    Live finance-specific insights

    See more
    • BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

      Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).  The trial design was previously agreed upon with the FDA under a Special Protocol Assessment (SPA), confirming the study's endpoints and statistical methodology are appropriate to support a future Biologics License Application (BLA) submissio

      5/19/25 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "BrainStorm continues to make meaningful progress in advancing our NurOwn® development program. Our priority continues to be initiation of a Phase 3b trial, designed to confirm the product's efficacy in early stage ALS patients and support a new BLA," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We h

      5/15/25 4:05:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19

      NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has rescheduled the release of its financial results for the first quarter ended March 31, 2025, to post-market close today, May 15. In addition, the Company has rescheduled its previously announced investor conference call, which will now take place on Monday, May 19, 2025, at 8:30 a.m. Eastern Time. BrainStorm's President & Chief Executive Officer, Chaim Lebovits, will present a corporate update to be followed by Q&A. Joining Mr. Lebovits to answer investment community questions will be Haro Hart

      5/15/25 7:30:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Leadership Updates

    Live Leadership Updates

    See more
    • BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

      Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK, June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.     Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for $73 mil

      6/20/24 6:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer

      Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm.  He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, includin

      7/12/23 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

      NEW YORK, June 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA (IMD), LL.M, as Board Member, chairman of its Audit Committee and member of its Governance, Nomination and Compensation Committee (GNC), effective June 20. Mr. Naor is replacing Mr. Malcolm Taub, who will retire from the same roles after 14 years of service on the Company's board of directors. "We welcome the addition of Nir as a new independent board member, and we are confident that his impressive corporate experience in both the U.S. and Europe will add further

      6/20/23 9:06:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brainstorm Cell upgraded by Maxim Group

      Maxim Group upgraded Brainstorm Cell from Hold to Buy

      2/5/21 8:55:41 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brainstorm Cell Therapeutics upgraded by Maxim Group with a new price target

      Maxim Group upgraded Brainstorm Cell Therapeutics from Hold to Buy and set a new price target of $12.00

      2/4/21 1:51:23 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

      SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      11/14/24 3:24:53 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

      SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      11/13/24 7:55:51 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Brainstorm Cell Therapeutics Inc. (Amendment)

      SC 13G/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      2/12/24 10:06:24 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care